Mallinckrodt Pharmaceuticals is an American-Irish domiciled manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. In 2017 it generated 90% of its sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt’s 2013 tax inversion to Ireland drew controversy when it was shown Acthar was Medicaid’s most expensive drug.
Mallinckrodt acquires (for repricing), manufactures, and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the acquisition, manufacture, and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products, and radiopharmaceuticals.[5] The company employed 5,500 and had net sales of $3.2 billion in 2017; of which $2.9 billion was from the U.S. healthcare system.
The company has been implicated as a major contributor to the prescription opioid scandal around the over-prescription of oxycodone in the United States.
Head Office Location: Blanchardstown, Dublin, Ireland
Frequently Hiring
- Maintenance Manager
- EHS Business Partner, Manager
- Senior Project Engineer
- Maintenance Project Engineer
- Biomanufacturing Technician
- Maintenance & Reliability Manager
- Director, Global Engineering & EHS
- Supervisor, Production
- Maintenance Supervisor
- Sr. Process Safety Specialist
- Sr. Health and Safety Engineer
- Principal Formulations Scientist
- Mechanical Integrity/Reliability Engineer
- Sr. Chemical Process Engineer
- I&E Technician